AbbVie Inc. stock holds near highs as Apogee deal and guidance support sentiment
Published on 09/06/2026 at 15:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. stock (ISIN US00287Y1091) is trading at about 256.53 USD as of September 6, 2026, keeping the large cap biopharma group close to its 12 month high of 267.47 USD while investors weigh fresh deal activity and updated guidance.
Market price and guidance in focus
According to recent market data, AbbVie shares traded between 255.00 USD and 259.60 USD on September 6, 2026, closing around 256.53 USD with trading volume of 4.73 million versus an average of 3.89 million shares, highlighting elevated interest in the name.
Stock portal analyses compiled on September 6, 2026 indicate that AbbVie currently carries a consensus rating described as Moderate Buy with an average target price of 275.95 USD, implying about 7.6 percent upside from the recent 256.27 USD quote used in several institutional holding reports.
Earnings momentum and 2026 outlook
In its latest quarter, AbbVie reported net revenues of 16,990 million USD for Q2 2026, taking first half 2026 revenues to 31,992 million USD, which represents year over year growth of 10 percent and 11 percent respectively compared with the same periods in 2025, according to an earnings summary based on the company’s most recent Form 10-Q filing.
The same mid year overview shows operating earnings of 6,432 million USD in Q2 2026 and 10,422 million USD for the first six months of 2026, while diluted earnings per share reached 2.03 USD for the quarter and 2.42 USD year to date, underscoring continued profitability despite portfolio transitions.
Analyst data cited by several institutional investor filings on September 6, 2026 point to adjusted earnings per share guidance for fiscal year 2026 in a range of 13.87 USD to 14.07 USD, with specific Q3 2026 guidance of 3.84 USD to 3.88 USD per share; consensus forecasts cluster around 14.05 USD earnings per share for the full year, suggesting mid single digit growth versus 2025.
Further figures and news on AbbVie Inc.
More regulatory filings, earnings details and news about AbbVie Inc. can be found in the curated overview for this ISIN on ad-hoc-news.de.
Revenue mix and segment dynamics
A detailed review of AbbVie’s 2026 mid year results shows that immunology remains the core growth engine: Q2 2026 revenues from Skyrizi reached 5,505 million USD, while Rinvoq contributed 2,525 million USD, jointly offsetting ongoing declines in legacy blockbuster Humira and supporting the double digit revenue expansion.
Neuroscience brands also added momentum in Q2 2026, with therapies such as Vraylar, Botox Therapeutic, Ubrelvy, Qulipta and Vyalev posting broad double digit growth compared with the prior year period, whereas certain mature assets like Imbruvica, Mavyret and parts of the aesthetics portfolio saw contracting sales.
Cash flows from operations amounted to 7,265 million USD over the first half of 2026, enabling AbbVie to fund 6,148 million USD in dividend payments and 1,498 million USD of share repurchases, while also issuing 8,000 million USD of new senior notes to support longer term investment and capital allocation plans.
Apogee Therapeutics acquisition and pipeline
Beyond organic growth, AbbVie has also been active on the deal side: on September 3, 2026, the company completed its 10.9 billion USD acquisition of Apogee Therapeutics, adding late stage and early stage immunology assets to its pipeline, as summarized in a recent market news roundup.
The Apogee transaction is described as AbbVie’s largest bolt on acquisition since 2019 and is intended to deepen its presence in immune mediated diseases, a strategy that complements the strong uptake seen in Skyrizi and Rinvoq and aims to keep the portfolio competitive as biosimilar pressure on older products builds.
Interest in AbbVie’s innovation pipeline has also been supported by positive topline results from the Phase 3 CERVINO trial of etentamig, an investigational BCMA x CD3 bispecific T cell engager in relapsed or refractory multiple myeloma, with recent summaries noting that the study met dual primary endpoints in overall response rate and progression free survival.
Key product: Skyrizi in immunology
One representative product for AbbVie’s current strategy is Skyrizi, a humanized monoclonal antibody targeting the p19 subunit of interleukin 23 and approved in major markets for indications such as moderate to severe plaque psoriasis, psoriatic arthritis and Crohn’s disease.
In Q2 2026, Skyrizi’s 5,505 million USD revenue contribution not only marked a substantial increase versus the prior year but also underlined how quickly the therapy has become a cornerstone of AbbVie’s immunology franchise, helping to diversify away from older assets and underpinning the company’s confidence in its 2026 earnings guidance.
AbbVie Inc. stock near 12 month high
As of September 6, 2026, AbbVie Inc. stock around 256.53 USD on the New York Stock Exchange trades not far below its 12 month high of 267.47 USD and clearly above its 12 month low of 190.75 USD, reflecting investors’ willingness to pay a premium for the combination of dividend income, pipeline news and solid earnings guidance.
AbbVie Inc. at a glance
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Trading venue: NYSE
- Price (as of September 6, 2026): 256.53 USD
- Market capitalization: 453.04 billion USD (as of September 6, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
